March 2024 in “Journal of the American Academy of Dermatology” Taking medication for hair loss might cause sexual problems.
January 2026 in “Nutrición Hospitalaria” Many drugs can cause lipid metabolism issues, and labels need better warnings.
28 citations
,
December 2001 in “European Journal of Pharmacology” M50054 may help treat hepatitis and hair loss from chemotherapy.
44 citations
,
December 2005 in “The Journal of Steroid Biochemistry and Molecular Biology” Combining 5α-reductase and aromatase inhibitors may better reduce estrogen levels.
July 2014 in “Urologia Journal” 5ARI treatment improves PSA test accuracy for prostate cancer diagnosis.
The document explains how certain drugs block hormones to treat cancers like breast and prostate cancer.
September 2020 in “Current Enzyme Inhibition” Three compounds were found to inhibit a prostate disease-related enzyme and reduce prostate size more effectively than the current treatment, suggesting they could be used for treating benign prostatic hyperplasia.
February 2026 in “Mendeley Data” Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.
November 2012 in “Journal of the International AIDS Society” Antiretrovirals can affect finasteride's effectiveness, so dose adjustments may be needed for men on HIV treatment.
17 citations
,
December 2004 in “Bioorganic & Medicinal Chemistry Letters” Scientists found new, better-working inhibitors for a hormone-related enzyme.
14 citations
,
February 2011 in “Drug Metabolism and Disposition” Ketoconazole increases finasteride's effectiveness and lifespan in the body.
124 citations
,
January 1993 in “The Prostate” Finasteride effectively inhibits 5α reductase, while plant extracts like Permixon and Bazoton don't show significant results.
12 citations
,
November 2024 in “Plants” Phytosterols may help manage prostate issues but are less effective than synthetic drugs.
42 citations
,
April 2021 in “Pharmaceuticals” Five FDA-approved drugs may help block COVID-19 virus entry.
54 citations
,
May 2015 in “Endocrinology” Manipulating 5α-reductase type 2 can affect liver fat production and glucocorticoid effects.
30 citations
,
September 2016 in “BMJ” Taking 5-α reductase inhibitors for prostate enlargement or hair loss does not significantly raise the risk of erectile dysfunction.
8 citations
,
April 2021 in “Journal of Clinical Investigation” Finasteride reduces opioid use and withdrawal symptoms in animals.
66 citations
,
June 2013 in “Journal of Dermatological Treatment” Finasteride and dutasteride effectively treat hair loss, but may cause side effects like sexual dysfunction and depression.
15 citations
,
February 2021 in “Scientific Reports” RNA aptamers can specifically block FGF5-related cell growth, potentially treating related diseases or hair disorders.
218 citations
,
December 2011 in “Advances in Urology” The document concludes that the 5 alpha-reductase enzymes are important in steroid metabolism and related to various human diseases, with inhibitors used to treat conditions like male pattern baldness and prostate issues.
10 citations
,
March 2023 in “Journal of Chemistry” New compounds show promise for treating benign prostate hyperplasia with fewer side effects.
January 2026 in “Figshare” Finasteride can cause melasma, especially in people with darker skin.
5 citations
,
January 2014 in “Molecular Simulation” A new compound may treat benign prostatic hyperplasia better than finasteride.
February 2026 in “NeuroSci” Finasteride and dutasteride may cause depression and anxiety, especially in younger men.
237 citations
,
December 2001 in “Urology” Blocking the enzyme 5α-reductase can shrink the prostate and help treat enlarged prostate issues.
November 2025 in “Mendeley Data” Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.
22 citations
,
January 2001 in “Chemical & Pharmaceutical Bulletin” Some new progesterone derivatives are better at blocking testosterone conversion than a common drug.
17 citations
,
October 1994 in “The Journal of Clinical Endocrinology and Metabolism”
April 2024 in “The Journal of urology/The journal of urology” 5-alpha-reductase inhibitors lower PSA density but higher PSA density indicates disease progression.
28 citations
,
August 2014 in “Cancer Causes & Control” Taking 5α-reductase inhibitors does not significantly increase the risk of breast cancer in men.